PMC:7324763 / 80281-81494
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1288 | 24-30 | UBERON:0002405;GO:0006955 | denotes | immune |
T1289 | 31-41 | GO:0006955 | denotes | modulating |
T1290 | 81-89 | SP_7 | denotes | COVID-19 |
T1291 | 174-185 | NCBITaxon:1 | denotes | individuals |
T1292 | 429-440 | NCBITaxon:1 | denotes | Individuals |
T1293 | 470-478 | SP_7 | denotes | COVID-19 |
T1294 | 589-595 | UBERON:0002405 | denotes | immune |
T1295 | 819-827 | SP_7 | denotes | COVID-19 |
T1296 | 962-979 | CHEBI:35705;CHEBI:35705 | denotes | immunosuppressive |
T1297 | 1068-1074 | UBERON:0002405 | denotes | immune |
T1298 | 1116-1125 | CHEBI:21241;CHEBI:21241 | denotes | vitamin C |
T1299 | 1130-1139 | CHEBI:27300;CHEBI:27300 | denotes | vitamin D |
T1300 | 1195-1203 | SP_7 | denotes | COVID-19 |
T78105 | 24-30 | UBERON:0002405;GO:0006955 | denotes | immune |
T77112 | 31-41 | GO:0006955 | denotes | modulating |
T97273 | 81-89 | SP_7 | denotes | COVID-19 |
T54596 | 174-185 | NCBITaxon:1 | denotes | individuals |
T6473 | 429-440 | NCBITaxon:1 | denotes | Individuals |
T17163 | 470-478 | SP_7 | denotes | COVID-19 |
T17141 | 589-595 | UBERON:0002405 | denotes | immune |
T47170 | 819-827 | SP_7 | denotes | COVID-19 |
T91081 | 962-979 | CHEBI:35705;CHEBI:35705 | denotes | immunosuppressive |
T91334 | 1068-1074 | UBERON:0002405 | denotes | immune |
T9380 | 1116-1125 | CHEBI:21241;CHEBI:21241 | denotes | vitamin C |
T99008 | 1130-1139 | CHEBI:27300;CHEBI:27300 | denotes | vitamin D |
T12216 | 1195-1203 | SP_7 | denotes | COVID-19 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T906 | 629-636 | Body_part | denotes | NK cell | http://purl.org/sig/ont/fma/fma63147 |
T907 | 632-636 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T561 | 81-89 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T562 | 470-478 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T563 | 819-827 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T564 | 1195-1203 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T946 | 151-152 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T947 | 198-199 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T948 | 426-427 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | B |
T949 | 450-456 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T950 | 629-636 | http://purl.obolibrary.org/obo/CL_0000623 | denotes | NK cell |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T903 | 1116-1125 | Chemical | denotes | vitamin C | http://purl.obolibrary.org/obo/CHEBI_21241 |
T212 | 1116-1123 | Chemical | denotes | vitamin | http://purl.obolibrary.org/obo/CHEBI_33229 |
T213 | 1130-1139 | Chemical | denotes | vitamin D | http://purl.obolibrary.org/obo/CHEBI_27300 |
T56457 | 1130-1137 | Chemical | denotes | vitamin | http://purl.obolibrary.org/obo/CHEBI_33229 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2233 | 90-98 | Species | denotes | patients | Tax:9606 |
2234 | 828-836 | Species | denotes | patients | Tax:9606 |
2235 | 1204-1212 | Species | denotes | patients | Tax:9606 |
2236 | 1116-1125 | Chemical | denotes | vitamin C | MESH:D001205 |
2237 | 1130-1139 | Chemical | denotes | vitamin D | MESH:D014807 |
2238 | 81-89 | Disease | denotes | COVID-19 | MESH:C000657245 |
2239 | 222-230 | Disease | denotes | infected | MESH:D007239 |
2240 | 470-478 | Disease | denotes | COVID-19 | MESH:C000657245 |
2241 | 819-827 | Disease | denotes | COVID-19 | MESH:C000657245 |
2242 | 1026-1034 | Disease | denotes | toxicity | MESH:D064420 |
2243 | 1195-1203 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T486 | 0-653 | Sentence | denotes | Figure 2 Short-list of immune modulating therapies undergoing clinical trial in COVID-19 patients and recommendations on who should receive therapy. (A) Healthy, uninfected individuals, who are at a high risk of becoming infected (through situational circumstances such as healthcare workers) would be most fit and suitable to receive investigational prophylactic therapies such as exogenous IFNs and heterologous vaccines. (B) Individuals who have tested positive for COVID-19 that are asymptomatic or have mild to moderate disease progression may benefit from receiving investigational immune stimulating therapies, including NK cell-based therapies. |
T487 | 654-990 | Sentence | denotes | It is critical that investigators must be vigilant to assess the safety profile and potential immunopathologies associated with these immunotherapies. (C) In severe COVID-19 patients, the most appropriate therapies to investigate would be those that mitigate immunopathologies, such as anti-inflammatory and immunosuppressive therapies. |
T488 | 991-1213 | Sentence | denotes | Given the relatively low chance of toxicity and the wide range of beneficial immune effects, natural health products such as vitamin C and vitamin D can be suitable for investigation at all categories of COVID-19 patients. |